Clomid 50mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Clomifene citrate

Available from:

Waymade Healthcare Plc

ATC code:

G03GB02

INN (International Name):

Clomifene citrate

Dosage:

50mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 06050100

Patient Information leaflet

PACKAGE LEAFLET:
INFORMATION FOR THE USER
CLOMID® 50MG TABLETS
clomifene citrate
Is this leaflet hard to see or read?
Phone no - 08453727101 for help
READ
ALL
OF
THIS
LEAFLET
CAREFULLY
BEFORE
YOU
START TAKING THIS MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor
or pharmacist.
• This medicine has been prescribed to you only. Do
not pass it on to others. It may harm them, even if
their signs of illness are the same as yours.
• If you get any side effects, talk to your pharmacist.
This includes any possible side effects not listed in
this leaflet (see section 4).
WHAT IS IN THIS LEAFLET:
1.
What Clomid is and what it is used for
2.
What you need to know before you take Clomid
3.
How to take Clomid
4.
Possible side effects
5.
How to store Clomid
6.
Contents of the pack and other information
1. WHAT CLOMID IS AND WHAT IT IS USED FOR
Clomid
contains
a
medicine
called
clomifene
citrate. This belongs to a group of medicines called
ovulation stimulants. It works by stimulating the
release of eggs from the ovary (ovulation). Clomid is
used for some types of infertility, in women who are
not ovulating properly.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE
CLOMID
BEFORE YOU TAKE THE MEDICINE TALK TO YOUR
DOCTOR ABOUT THE RISKS OF:
Becoming pregnant with more than one child at
the same time (multiple pregnancies)
Pregnancies where the baby grows outside of the
womb (ectopic)
A possible increased risk of ovarian cancer
Any pregnancy could lead to birth defects or
miscarriage. This can happen even if you are not
taking Clomid. You should talk to your doctor
about the possible risks before you take Clomid.
DO NOT TAKE THIS MEDICINE AND TELL YOUR
DOCTOR IF:
You are allergic (hypersensitive) to clomifene or
any of the other ingredients of Clomid (listed in
Section 6 below). Signs of an allergic reaction
include: a rash, swallowing or breathing problems,
swelling of your lips, face, throat or tongue
You have or e

Summary of Product characteristics

1.
NAME OF THE MEDICINAL PRODUCT
Clomid™ 50mg Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Clomifene Citrate 50mg_ _
3.
PHARMACEUTICAL FORM
Tablet
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Clomid 50mg Tablets 50mg Tablets (Clomifene Citrate BP) is indicated
for the treatment of
ovulatory failure in women desiring pregnancy. Clomid 50mg Tablets
50mg Tablets is
indicated only for patients in whom ovulatory dysfunction is
demonstrated. Other causes of
infertility must be excluded or adequately treated before giving
Clomid 50mg Tablets 50mg
Tablets.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Route of Administration
Oral
Adults Only:
The recommended dose for the first course of Clomid 50mg Tablets 50mg
Tablets (Clomifene
Citrate BP) is 50mg (1 tablet) daily for 5 days. Therapy may be
started at any time in the patient who
has had no recent uterine bleeding. If progestin-induced bleeding is
planned, or if spontaneous
uterine bleeding occurs before therapy, the regimen of 50mg daily for
5 days should be started on or
about the fifth day of the cycle. When ovulation occurs at this
dosage, there is no advantage to
increasing the dose in subsequent cycles of treatment.
If ovulation appears not to have occurred after the first course of
therapy, a second course of 100mg
daily (two 50mg tablets given as a single daily dose) for 5 days
should be given. This course may be
started as early as 30 days after the previous one. Increase of the
dosage or duration of therapy
beyond 100mg/day for 5 days should not be undertaken.
The majority of patients who are going to respond will respond to the
first course of therapy, and 3
courses should constitute an adequate therapeutic trial. If ovulatory
menses have not yet occurred,
the diagnosis should be re-evaluated. Treatment beyond this is not
recommended in the patient who
does not exhibit evidence of ovulation.
_Long-term cyclic therapy. _
_ _
Not recommended.
The relative safety of long-term cyclic therapy has not been
conclusively demonstrated and, since the
majorit